ResMed Inc. (NYSE:RMD) Shares Acquired by Versant Capital Management Inc

Versant Capital Management Inc boosted its holdings in ResMed Inc. (NYSE:RMD) by 66.3% during the 4th quarter, Holdings Channel reports. The fund owned 459 shares of the medical equipment provider’s stock after acquiring an additional 183 shares during the quarter. Versant Capital Management Inc’s holdings in ResMed were worth $105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. True Wealth Design LLC increased its holdings in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 110 shares during the period. Ashton Thomas Securities LLC bought a new position in ResMed in the 3rd quarter valued at about $34,000. Capital Performance Advisors LLP acquired a new position in ResMed during the 3rd quarter valued at about $60,000. Quest Partners LLC increased its stake in ResMed by 44.1% during the 2nd quarter. Quest Partners LLC now owns 327 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 100 shares during the period. Finally, Quarry LP raised its position in shares of ResMed by 271.9% during the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 242 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

Wall Street Analysts Forecast Growth

RMD has been the topic of a number of research analyst reports. Robert W. Baird raised their price objective on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Royal Bank of Canada lifted their price target on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research report on Friday, October 25th. Baird R W raised ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, KeyCorp boosted their price target on shares of ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and an average target price of $227.91.

ResMed Price Performance

RMD stock opened at $231.67 on Friday. ResMed Inc. has a one year low of $164.12 and a one year high of $260.49. The firm has a 50-day moving average of $240.72 and a two-hundred day moving average of $229.83. The firm has a market capitalization of $34.01 billion, a PE ratio of 30.68, a P/E/G ratio of 1.73 and a beta of 0.70. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter last year, the business posted $1.64 EPS. The company’s revenue was up 11.1% on a year-over-year basis. On average, analysts forecast that ResMed Inc. will post 9.34 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Thursday, November 7th were paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.92%. The ex-dividend date was Thursday, November 7th. ResMed’s dividend payout ratio is currently 28.08%.

Insiders Place Their Bets

In other ResMed news, Director Witte Jan De sold 796 shares of ResMed stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the sale, the director now owns 6,723 shares of the company’s stock, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total transaction of $497,480.00. Following the completion of the transaction, the director now directly owns 83,204 shares in the company, valued at $20,696,162.96. This trade represents a 2.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 45,725 shares of company stock worth $10,779,048. 0.71% of the stock is currently owned by company insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.